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1. Introduction
Tranexamic acid [trans-4-(aminomethyl)cyclohexane-1-carboxylic
acid] (TXA, Fig. 1, 1) is a synthetic derivative of the amino acid lysine de-
veloped in 1960's and introduced into clinical practice N40 years ago.
TXA is a biologically active compound with antifibrinolytic effect. It re-
versibly blocks the lysine binding sites on plasminogen through forma-
tion of a reversible complex of the drug with plasminogen molecules
disrupting the action of plasmin and preventing the dissolution of the fi-
brin clot [1–4]. As a result, TXA is associated with reduction of bleeding
due to its inhibitory effect on clot breakdown.
TXAwas recently included in theWorldHealth Organization (WHO)
core list of essential medicines for use in adult trauma patients with on-
going significant haemorrhage, or at risk of significant haemorrhage
within 8 h of injury [5]. This list contains minimum medicine needs
for a basic health-care system which gives the most efficacious, safe
and cost-effective medicines for priority conditions. Its usefulness has
been reported in a wide range of clinical conditions to manage abnor-
mal bleeding or bleeding tendencies in which local or systemic
hyperfibrinolysis is considered to be involved [4,6–8]. TXA is employed
to treatwomen suffering frommenorrhagia, bleeding during pregnancy
and for prevention and treatment of postpartumhaemorrhage, in upper
gastrointestinal bleeding, bleeding after cardiac surgery, to reduce
blood loss and transfusion in trauma patients, etc. [9–12]. The therapeu-
tic value of TXA has been also considered in the prevention of human
ovarian carcinoma cell growth [13,14]. Other potential clinical and cos-
metic applications have been proposed for TXA namely treatment of ul-
traviolet radiation-induced pigmentation and suppression of ultraviolet
B eye irradiation-induced melanocyte activation [15–20].
The interest on TXA overwhelmingly grew after withdraw, in 2008,
of the antifibrinolytic agent aprotinin, a serine protease inhibitor [21,
22]. TXA has been associated, however, with an increased incidence of
postoperative seizures and has led to adverse neurological outcomes,
longer hospital stays, and increased in-hospital mortality [23]. The
lack of pharmacokinetic and pharmacodynamic data, in different age
groups undergoing different surgeries, reinforce the difficulties to de-
fine the optimum therapeutic plasma concentration of TXA needed to
safely inhibit fibrinolysis in the perioperative period. Some dosing
scheduleswere based on doses previously determined to inhibit plasma
fibrinolytic activity in different settings; while others were developed
empirically. Clinical trials performed so far suggest a wide variability
in response to TXA. Thus, a renewed attention to TXA has emerged in
the literature as the pharmacokinetic, optimum dose and administra-
tions schedules of this drug are still subject of research.
The present paper aims to provide an updated review of the analyt-
ical methods reported for the determination of this compound in bio-
logical material such as plasma, serum and urine. The review covers
and critically addresses an extensive selection of instrumental analytical
techniques ranging from liquid and gas chromatography to electropho-
resis, automated and electroanalytical approaches. Attention is also paid
on sample preparation protocols focusing on biological material.
2. Determination of TXA in biological fluids
In what concerns biological matrices, TXA has been mainly deter-
mined in human plasma and serum as summarized in Tables 1, 2 and
3. Because of the complexity of the biological matrices, most of the
techniques require a careful and extensive sample pre-treatment,Fig. 1. Chemical structures of tranexamic acid (1 and 2) and ε-aminocaproic acid (3).to remove potential interferences, namely proteins and branched-
chain amino acids. As TXA has a structural resemblance to amino
acids, the concomitant presence of these molecules in biological
samples can interfere upon separative procedures prior to analysis.
The most commonly used methods associate reversed-phase
HPLC to fluorescence [24–29] or UV [30–32] detection, as depicted
in Fig. 2. Considering that TXA does not possess in its chemical struc-
ture a chromophore or fluorophore, exhibiting therefore a poor ab-
sorption at 220 nm, a derivatisation step is, in most cases, needed
to increase the methods' sensitivity. More recently, several methods
have been developed based on chromatographic techniques coupled
to mass spectrometry [33–41]. MS detection enables straightforward
analyte identification and quantification eliminating the need of any
derivatisation procedure, which may introduce large assay varia-
tions, namely the stability of the newly formed derivative. Less com-
mon applications reporting the determination of TXA include
techniques such as capillary electrophoresis and paper electrophore-
sis coupled to UV–Vis detection [42,43].
2.1. Sample preparation
Generally, the determination of TXA concentration in plasma or
serum obtained from collected human blood requires firstly the
deproteinization of the samples, after addition of the chosen internal
standard (IS) if used (Tables 1, 2 and 3). A fluxogram of method anal-
ysis focused on sample treatment strategies used for TXA is present-
ed in Fig. 3.
Several protein precipitation reagents have been applied to achieve
this goal, specifically picric acid [42,44], heptafluorobutyric acid [33],
perchloric acid [25,34,35,43], methanol [37,41], ethanol [26,30], and
acetonitrile [24,28,31,39,45,46], which is in fact the most commonly
used. Fiechtner et al. [28] reported the pre-treatment of plasma samples
with leucine dehydrogenase prior to deproteinization by acetonitrile.
This enzyme was used to minimize interferences by branched-chain
amino acids since it is highly specific for these compounds [47].
Depending on the precipitation reagent used and if a derivatisation
procedure is followed, pH adjustment might be necessary [24,26,30,
31,35,44]. If one chooses to use a mass spectrometer as detection sys-
tem, the supernatant can, at this stage, be transferred into an auto-sam-
pler vial and subsequently injected into, for example, the LC-MS or LC-
MS/MS system [34,39]. In other cases, the supernatant is dried, the res-
idue retaken in the mobile phase and injected [37].
Solid phase microextraction (SPME) has also been applied to the de-
termination of TXA concentration in human plasma [36,38,40,48]. The vi-
ability of this technique in clinical use for the analysis of polar drugs such
as TXAwas first established by Bojko et al. [36] by analysing plasma sam-
ples from patients who underwent heart surgery with the use of cardio-
pulmonary bypass (CPB). For this, commercial thin-film microextraction
(TFME) fibers coated with octadecyl carbon chains (C18) were used after
preconditioning overnight in amethanol:water (1:1, v/v) solution. Based
on studies performed to evaluate the extraction time profile and to im-
prove the method sensitivity, 300 μL of sample were exposed to the
fiber for 90 min with vortex agitation at 1200 rpm, followed by rinsing
with purified water for 30 s. The fiber was then placed, for desorption,
in a mixture of ACN:water (4:1, v/v) with 0.1% (v/v) formic acid using
the same type of agitation. The efficiency of this method was compared
with standard techniques such as protein precipitation and ultrafiltration
and the results revealed that the accuracy and precision obtained were
equivalent. The linear ranges of TXA concentration in plasma samples ob-
tained for this SPME procedure was 1.56–25 and 25–300 μg mL−1 [36].
Bojko et al. [40] latter developed an automated TFME procedure,
where a polyacrylonitrile-C18 60 μmthin-filmwas applied to covermin-
iaturized stainless steel blades. The amount of analyte extracted in this
modified format was 12 times higher when compared to conventional
fibers [36]. However, both procedures required an extensive time for
extraction and desorption, around 2 h for each step. Considering the
Table 1
Summary of analytical methods using mass spectrometry detection for the quantification of tranexamic acid in biological fluidsa,b.
Sample Separative
technique
Ionization system/SRM Sample preparation Derivatisating
agent
Column and eluent IS LOD and LOQ Linear range Ref.
Plasma HPLC ESI+; m/z 157.8 N 95.2 SPME (C18 fibers); desorption with
ACN:H2O (4:1, v/v) plus 0.1% (v/v) formic
acid by vortex agitation at 1200 rpm for
90 min
– HILIC, ammonium formate
buffer:ACN binary gradient, pH 3.5
– 0.5 and 1.5 μg mL−1 1.56–300 μg mL−1 [36]
Plasma HPLC ESI+; m/z 157.8 N 95.2 Automated TF-SPME, polyacrylonitrile C18
96 thin-film SPME coating; 20 min at 1000
rpm for extraction; blades washed for 10 s
with purified H2O; desorption using 1.5 mL
of ACN:H2O (4:1, v/v) with 0.1% v/v of
formic acid at 1200 rpm
– HILIC, ammonium formate
buffer:ACN binary gradient, pH 3.5
– 0.5 and 1 μg mL−1 1.0–300 μg mL−1 [40]
Plasma HPLC ESI+; m/z 158 N 95; IS
212 N 166
Deproteinization with perchloric acid
(vortex 30 s; 16,000g × 10 min) and direct
injection of supernatant
– XTerra MS C18, 2 mM ammonium
acetate buffer:ACN (90:10, v/v),
pH 3.5
Methyldopa 0.01 and 0.02 μg mL−1 0.02–10.00 μg mL−1 [34]
Plasma HPLC ESI+; m/z 158 N 123; IS
144 N 109
WCX TF-SPME; desorption with
MeOH:ACN:ammonium formate buffer
(3:3:4, v/v/v) plus 1.5% formic acid for 10
min at 850 rpm
– Bonus-RP, ammonium formate
buffer:ACN plus 0.1% formic acid
binary gradient, pH 3.0
Cis-4-
aminocyclohexane
carboxylic acid
0.04 and 0.1 μg mL−1 0.25–300 μg mL−1 [38]
Plasma UPLC ESI+; m/z 158.15 N
140.68; IS 161.17 N
142.76
Deproteinization with ACN (vortex 30 s;
13,000 rpm, 4 min) and direct injection of
supernatant
– BEH amide, water:ACN both
containing 0.1% formic acid
(20:80, v/v)
13C2,15N,cis-TXA 0.38 and 0.76 mg L−1 0.8–200 mg L−1 [39]
Plasma and CSF UPLC ESI+; m/z 158.2 N 95.2;
IS 132.1 N 114.0
Deproteinization with MeOH (vortex 30 s;
16,000g × 10 min)
– BEH C18, H2O and MeOH gradient
both containing 2 mM ammonium
acetate and 0.1% formic acid
ACA 0.1 μg mL−1 (LOQ) 0.1–10.0 μg mL−1 [37]
Serum HPLC ESI+; m/z 158.0 N
122.7; IS 144.0 N 126.0
Deproteinization with perchloric acid
(vortex 30 s; 14,000 rpm × 10 min); pH
adjustment to 3–4 with sodium hydroxide
– HyPurity C18, 2 mmol/L NH4COOH
buffer:ACN (95:5, v/v), pH 3.8
Cis-4--
aminocyclohexane
carboxylic acid
0.05 and 1.0 μg mL−1 1.0–200.0 μg mL−1 [35]
Serum GC EI Deproteinization with MeOH
(3000g × 20 min)
ECF HP-5 ACA 0.2 and 0.6 μg mL−1 0.6–5.0 μg mL−1 [41]
Serum GC EI Deproteinization with heptafluorobutyric
acid (10 min shaking by hand; 2000 rpm ×
15 min)
HFBA Chromosorb W-HP 80–100 TXA-d6 NA 1–5 ng [33]
ACA, ε-aminocaproic acid; BEH, ethylene bridged hybrid; CSF, cerebral spinal fluid; ECF, ethyl chloroformate; HFBA, heptafluorobutyric anhydride; LOD, limit of detection; LOQ, limit of quantification; NA, not available; WCX TF-SPME, weak cation
exchange thin-film solid-phase microextraction.
a HPLC conditions are reverse phase unless stated otherwise.
b All samples were collected from humans unless otherwise indicated.
Table 2
Summary of analytical methods using UV–Vis detection for the quantification of tranexamic acid in biological fluidsa,b.
Sample Separative
technique
Detection
wavelength
Sample preparation Derivatisating agent Column and eluent IS LOD and LOQ Linear range Ref.
Blood HPLC 317 nmc Deproteinization with ACN; pH
adjusted to 7 with sodium acetate
buffer
2-Hydroxy-1-naphthaldehyde YMC-ODS, MeOH:H2O:DCM:ACN
(58:35:5:2, v/v/v/v)
– 3 ng 30–90 ng [31]
Plasma CZE 300 nm Deproteinization with perchloric acid
(vortex 30 s; 10,000 rpm × 10 min)
OAC Uncoated fused-silica capillary,
phosphate buffer at 25 °C, pH 3.00
4-(Dimethylamino)
benzoic acid
2.5 μM (LOD) 10–200 μM [43]
Plasma and HaCaT UPLC 250 nm Plasma: deproteinization with ACN
(vortex; 14,800g × 6 min); DLLME
DNS-Cld ACQUITY UPLC BEH C18, H2O and
ACN gradient both containing
0.1% formic acid
Ethyl paraben Plasma: 3 pmol (LOD) Plasma: 5–500 μM [45]
HaCaT: 24 h incubation with TXA;
washed with PBS and lysed with
NP-40 lysis buffer for 30 min in ice;
10 min of ultrasonication and 3 cycles
of flash freezing; deproteinization
with ACN; DLLME
HaCaT: 0.03 pmol (LOD) HaCaT: NA
Serum HPLC 254 nm Deproteinization with ethanol (1500g
× 10 min); supernatant pH adjusted
to 9.2 with borax solution
Phenyl isothiocyanate Cosmosil 5C8, 20 mM phosphate
buffer:ethanol (90:10, v/v), pH 7.0
3-
Aminocyclohexane
carboxylic acid
0.2 μg mL−1 (LOD) 0.22–22.5 μg mL−1 [30]
Serume HPLC 205 nm Deproteinization with ACN (vortex
60 s; 10,000 rpm × 10 min)
– C18 Nucleosil, ACN:H2O (50:50,
v/v) adjusted with phosphoric
acid, pH 2.6
Propylparaben
sodium
12 and 40 ng mL−1 40–10.000 ng mL−1 [46]
Plasma and serumf HPLC NA Deproteinization with picric acid
(3000 rpm, 20 min); clean-up of
supernatant with Dowex 2-X8;
evaporation of solvent; pH
adjustment to 2
Ninhydrin Amberlite IR-120, eluent: NA – 0.2–0.3 mg/100 mL (LOQ) 0.02–0.18 μmol mL−1 [44]
Plasma and urine PE NA Deproteinization with picric acid;
pre-treatment on a cation exchange
resin (Dowex in H+ form)
Ninhydrin – – 0.5 μg mL−1 (LOQ) NA [42]
Urine HPLC 245 nm – Phenyl isothiocyanate Phenomenex Luna RP C18; 10 mM
phosphate buffer:ACN (65:35,
v/v), pH 3.6 (adjusted using
hydrochloric acid)
Heptaminol
hydrochloride
0.0379 and 0.126 μg mL−1 0.2–65 μg mL−1 [32]
BEH, ethylene bridged hybrid; DLLME, dispersive liquid-liquid microextraction; DNS-Cl, dansyl chloride; HaCaT, human keratinocyte cells; LOD, limit of detection; LOQ, limit of quantification; NA, not available; OAC, ofloxacin acyl chloride; PBS,
phosphate-buffered saline solution.
a HPLC conditions are reverse phase unless stated otherwise.
b All samples were collected from humans unless otherwise indicated.
c It is not clear if the optimum wavelength is 418 m or 317 nm.
d MW assisted.
e Simultaneous determination of TXA and losartan potassium.
f Rabbit plasma and serum were used.
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Fig. 2. Cumulative distribution of publications regarding assay of TXA in biological
samples, emphasizing the application of UV–Vis + FL detection (light gray), MS (dark
gray) and other (white) detection systems.analysis of a single sample, this time frame is excessive but real sample
analysis was performed under 96-well format, providing for instance 96
analysis in 35 min (mean sample preparation time of 22 s per sample)
[38].
2.2. Separative methods
Liquid chromatography (LC) is by far the analytical technique most
frequently chosen for the separation of TXA in biological samples, com-
prising generally a reversed phase column and a hydrophilic mobile
phase. Various stationary phases have been used (Tables 1, 2 and 3) al-
though the most extensively employed consists of C18 bonded to silica.
Acetonitrile is usually the elution solvent in combination with water
and/or a buffer solution (sodium phosphate, ammonium acetate) or
acid (acetic acid, phosphoric acid, hydrochloric acid or formic acid)
adjusting the pH from 2.6 to 5.5 (Tables 1, 2 and 3) [24,26,28,29,31,32,
34,35,37,45,46]. TXA contains two ionizable groups in its structure, a
carboxyl and an amino group (pKa 4.3 and 10.6), and is therefore, a
highly polar compound that exists as a zwitterion at physiological pH.
Hence, the success of its separation is highly dependent on the pH
value. For instance, the predominant form at pH 2.6 is the cationic spe-
cies while at pH 5.5 the zwitterion will predominate.
Other chromatographic RP mode phases, namely C8, were also ap-
plied [27,30]. Agilent Bonus-RP column was used as an alternative to
C18 and C8 alkyl bonded phases for the separation of TXA in biological
fluids [38]. This stationary phase is composed of a polar amine group
embedded in a long alkyl chain, thus reducing the interaction between
basic compounds and the silica. Also, diisopropyl side groups provide
steric protection against acid hydrolysis at low pH. Using HILIC technol-
ogy Pawliszyn et al. [36,40] achieved a retention time of 4.52 min in a
total run time of 12 min for TXA [40]. Delavenne et al. [39] reported
that, among several different analytical columns tested for tranexamic
acid, the BEH amide column (1.7 μm particles) showed the best perfor-
mance and efficiency, presenting a retention time of 2.75 min using a
mobile phase mixture of 20% aqueous + formic acid (0.1% v/v) and
79.9% of acetonitrile + formic acid (0.1% v/v).
GC analysis of TXA in biological samples (Table 1) has been also per-
formed but, due to TXA low volatility, it requires previous derivatisation
[33,41,49]. Miyazaki et al. [33] proposed a method based on the N-
heptafluorobutyryl amine derivative (Fig. 4, 4) using a Chromosorb
WHP column while maintaining the temperature of column oven at
185 °C. An alternative GC approach was reported by Abbasi et al. [41]
considering a non-polar HP-5 column using ethyl chloroformate as
derivatising reagent and MS detection. The obtained derivative (Fig. 4,
5) was separated using a temperature ramp from 100 to 200 °C.
Electron capture detection coupledwithGC column containing polar
phase 1% OV-225 on Chromosorb G at 250 °C has been also used for the
Fig. 3. Fluxogramofmethod analysis focus on sample treatment strategies used for plasma
and serum prior to TXA determination.quantification of TXA [49]. As TXAdoes not contain any functional group
with a strong detector response (e.g. halogens, phosphorus, peroxides
and nitro groups), derivatisation is mandatory with an electrophore,
such as the esterified N-(2′-nitro)-4′-trifluoromethylphenyl derivative
of TXA (Fig. 4, 6).
Capillary electrophoresis (CE) is often chosen to quantify drugs in
biological fluids. It has several advantages over conventional chro-
matographic techniques since this method requires smaller sample
volumes, minimal sample pre-treatment, low organic solvent con-
sumption, and simplicity of equipment that can be streamlined
through automation. This separation technique was applied to the
analysis of TXA in plasma samples through an electrophoretic deriv-
ative (Fig. 4, 7) using ofloxacin acyl chloride as derivatising reagent.
Capillary zone electrophoresis (CZE) was performed using an uncoated
fused-silica capillary and samples were injected at the anode using a
3.45× 103 Pa pressure during 3 swith applied voltage of 18 kV. The sep-
aration was achieved at 25 °C using a phosphate buffer solution at
pH 3.00 (125 mM) with a total run time of 10 min [43]. Since TXA and
TXA derivatives have both amino and carboxylic acid functionalities in
their structures, special care should be taken in what concerns the ap-
plied pH. The extension of ionization and therefore the balance between
the positively and negatively chargedmolecules may interfere with the
migration speed and therefore, the efficiency of separation. At pH 3.00,
the carboxylic group of TXA is predominantly protonated. An earlier
publication by Eriksson et al. [42] reported the separation of TXA from
human plasma and urine samples by paper electrophoresis usingmeth-
anol as eluent and ninhydrin as staining agent.
2.3. Detection systems
Mass spectrometry detectors coupled to liquid chromatography
are increasingly becoming the method of choice to determine TXA
in biological samples [33–41]. Among the different ionization
modes available for LC-MS and LC-MS/MS, ESI in positive mode was
commonly employed for TXA determination in biological fluids
(Table 1), using selected reaction monitoring (SRM) mode [34,36,
37,39]. The precursor to product ion transitions employed for TXA
quantification included the m/z transitions 158.2 N 95.2 [34,36,37]
and 158.2 N 140.7 [39]. Moreover, the secondmost abundant product
ions of the spectrum, corresponding to the m/z transitions 158.2
N 122.6, were used for identity confirmation in the work reportedFig. 4. Chemical structures ofN-heptafluorobutyryl amine (4), ethyl chloroformate (5), N-
(2′-nitro)-4′-trifluoromethylphenyl (6), and ofloxacin (7) derivatives of tranexamic
acid.by Delavenne et al. [39]. Both full scan MS/MS and SIM modes have
been likewise used for TXA quantification purposes [35,38]. The sin-
gle transition chosen for monitoring corresponded to them/z transi-
tion 158 N 123 [38]. Typically, for these methodologies, the detector
response was found to be linear within a concentration ranging from
0.02 to 300 μg mL−1 (Table 1).
Internal standards (IS) are often used to improve the precision of
quantitative analysis when using, for example, gas chromatography or
mass spectrometry detection. IS can also be used to correct variability
due to analyte loss in sample storage and treatment. When considering
LC-MS or LC-MS/MS methods the use of an appropriate IS enables the
control of the extraction procedure, LC injection, and ionization variabil-
ity. The use of this standard is beneficial, especially whenmultiple sam-
ple preparation steps are used. ForMSmethods, themost suitable IS are
isotope-labelled compounds because of their similar extraction recov-
ery, chromatographic behaviour, and ionization response to that of the
target analyte. In addition, isotope-labelled IS enable better compensa-
tion of the matrix effect on the ionization of the analyte.
The IS ε-aminocaproic acid (Fig. 1, 3) was used by Abou-Diwan et al.
[37] for the quantification of TXA in plasma and cerebral spinal fluid by
LC-MS/MS. Although this is not an isotope-labelled compound, the re-
tention times and m/z values for precursor ions (1.63 and 1.35 min;
158.2 and 132.1, for TXA and ACA, respectively) are similar enough to
not extend the overall time taken for each analysis, because this is one
of the most important parameters to take into account when bearing
in mind routine clinical use.
Chang et al. [34] used the commercially available methyldopa
(Fig. 5, 8), as internal standard, in the determination of TXA in
human plasma by LC-MS/MS. Methyldopa is known for its instability
due to potential oxidation of the 3,4-dihydroxypenyl group under
neutral or basic pH conditions but this was circumvented by adding
0.1% formic acid. Once more the choice of this IS did not delay the
chromatographic separation as typical retention times were 2.65 min
for TXA and 2.60 min for IS.
A more structurally similar IS to TXA, cis-4-aminocyclohexane-
carboxylic acid (Fig. 5, 9), was used to quantify TXA in human plasma
and serum by LC-MS/MS [35,38]. The structural difference between TXA
and this IS is a methylene group inserted between the cyclohexane ring
and the amine function, and a relatively similar retention time was ob-
tained for both. Delavenne et al. [39] used isotopically labelled TXA (Fig.
5, 10) which enhanced the robustness of the LC-MS/MS method but is a
more expensive alternative due to the cost of isotopically labelled
standards.
GC–MSmethods have also been applied to the determination of TXA
in human biological fluids using electron ionization (EI) [33,41]. Miya-
zaki et al. [33] reported an ionization energy and trap current of 20 eV
and 60 μA, respectively, with the ionization source at 250 °C and an ac-
celerating voltage of 3500 V. The quantification was based on the mon-
itoring of two characteristic fragment ions at m/z 308 (base peak) and
m/z 336 that correspond to the loss of the n-butyl ether and carbonyl
fragment, respectively, from the n-butyl ester N-heptafluorobutyryl de-
rivative of TXA (Fig. 4, 4). A GC–MS method in full scan mode using ε-
aminocaproic acid (Fig. 1, 3) as IS was proposed by Abbasi and co-
workers [41] operating with a EI source at 70 eV. MS source was kept
at 250 °C and the MS quadrupole at 230 °C.
UV detection coupledwith liquid chromatography has been used for
quantification of TXA on whole human blood, plasma, serum and urineFig. 5. Chemical structures of the internal standards used for TXA quantification in
biological fluids by LC-MS/MS: methyldopa (8), cis-4-aminocyclohexanecarboxylic acid
(9), 13C2,15N,cis-TXA (10).
Fig. 6. Chemical structures of the internal standards used for TXA quantification in
biological fluids by LC-UV: 3-aminocyclohexanecarboxylic acid (11), heptaminol
hydrochloride (12), ethyl paraben (13), sodium propylparaben (14), and 4-
(dimethylamino)benzoic acid (15).
Fig. 8. Chemical structures of derivatising agents applied in fluorescence detection of TXA,
including fluorescamine (20), o-phthalaldehyde (21), naphthalene-2,3-dicarboxaldehyde
(22), and dansyl chloride (23).(Table 2). Depending on the selected derivatising agent, and therefore,
on the chromophore attached to the TXA, UV detection was performed
using wavelengths ranging from 245 to 317 nm [30–32,45]. Typically,
for these methodologies, the detector response was found to be linear
within a concentration ranging from 0.2 to 79 μg mL−1 (Table 2).
Arayne et al. reported the quantification of TXA, without any
derivatisation, in human serum using UV detection at 205 nm. The de-
tector response was found to be linear for 0.04–10 μg mL−1 [46]. UV-
CZE has been developed and applied to the separation and determina-
tion of TXA in human plasma [43]. A phosphate buffer (125 mM,
pH 3.00) was employed as background electrolyte, enabling UV detec-
tion of the ofloxacin acyl derivative of TXA at 300 nm using a photodi-
ode array detector, with linearity in the range of 1.57–31.4 μg mL−1.
In UV and FL determination, IS are also applied for sample extraction
and LC injection control. Matsubayashi et al. [30] reported the use of
compound 3-aminocyclohexanecarboxylic acid (Fig. 6, 11), derivatised
with PITC, as internal standard for the LC-UV determination of TXA in
human serum. The authors reported that this IS raises concern in its
use since it can exist in two diastereomeric forms because it has
two chiral centres. These two chiral centres at the 1- and 3-positions
of the cyclohexane ring (Fig. 6, compound 11with chiral centres sig-
nalled with *) can occur in a mixture and produce, therefore, two
peaks in the chromatographic analysis corresponding to the cis- and
trans-isomer. Other IS have been used in the LC-UV quantification of
TXA in human plasma, serum and urine namely heptaminol hydrochlo-
ride (12) [32], ethyl paraben (13) [45], and propylparaben sodium (14)
[46] represented in Fig. 6. 4-(Dimethylamino) benzoic acid (Fig. 6, 15)
was used as IS in the quantification of TXA in plasma using CZE and
UV detection.
Fluorescence detection has shown to be useful for the determination
of TXA, upon derivatisation, in biological fluids [24–29]. Different ex-
citation and emission wavelengths were applied upon the chosen
derivatising agent (Table 3). For example, when using naphtha-
lene-2,3-dicarboxaldehyde (NDA) labelling the post-column fluo-
rescence detector is set with excitation and emission wavelengths
of 440 and 520 nm, respectively [29]. Linearity was attained for
0.08–15.7 μg mL−1.
Several compounds (Fig. 7) have been used successfully as IS for
fluorescence detection. However, the use of 4-aminomethylbicyclo-
[2.2.2]octane-1-carboxylic acid (Fig. 7, 16) as IS raised problems be-
cause a partial interference of arginine with the IS peak was observed
[25]. For pharmacokinetics and bioavailability studies of TXA in
human plasma, L-lysine hydrochloride (Fig. 7, 17) was chosen as ISFig. 7. Chemical structures of the internal standards used for TXA quantification in
biological fluids by LC-FL: 4-aminomethylbicyclo-[2.2.2]octane-1-carboxylic acid (16), L-
lysine hydrochloride (17), 4-(aminomethyl)cyclohexyl propionate hydrochloride (18),
and n-propylamine (19).[26] and for analysis of whole blood, 4-(aminomethyl)cyclohexyl
propionate hydrochloride (Fig. 7, 18) was employed as IS [27].
Huertas-Pérez et al. [29] tested several internal standards for quality
control purposes when studying the LC-FL quantification of TXA in
whole blood. Five commercially available amino compounds were
evaluated for the derivatisation reaction with naphthalene-2,3-
dicarboxaldehyde and cyanide, including n-propylamine (Fig. 7,
19), isopropylamine, n-dodecylamine, cyclohexylamine, and L-
DOPA (3,4-dihydroxy-L-phenylalanine). n-Propylamine was selected
because all the other IS had one or more of the following problems:
eluted too early which led to interferences from plasma components
(L-DOPA); eluted too late, increasing the time of analysis (n-
dodecylamine); high volatilitywhich led to lack of precision upon IS ad-
dition to sample (isopropylamine); and poor recovery from plasma due
to retention in filtering material (cyclohexylamine).
2.4. Derivatising agents
Many derivatisation reagents have been evaluated for detection of
trace amounts of TXA in biological samples by fluorimetry, namely
fluorescamine (FA) [24,27], o-phthalaldehyde [25,28], naphthalene-
2,3-dicarboxaldehyde (NDA) and cyanide [29], and dansyl chloride
(DNS-Cl) [26] (Fig. 8).
Two methods using fluorescamine (Fig. 8, 20) as the derivatising
agent for TXA or a pro-drug of TXA have been reported [24,27].
Fluorescamine has the advantage of reacting very fast with primary
amino groups to produce a fluorescent product, while the non-fluores-
cent unreacted fluorescamine hydrolyses in amatter of seconds to non-
fluorescent products being, therefore, effectively removed from the re-
action. However, due to its poor water solubility and high reactivity,
fluorescamine has to be added to samples dissolved in a water miscible
nonhydroxylic solvent [50]. Hence, fluorescamine, dissolved in acetoni-
trile or acetone, was found suitable for derivatising TXA in serum sam-
ples and blood at room temperature at pH 7–8 [24,27]. It forms, with
TXA, a strongly fluorescent product that can be detected at λexc =
390 nm and λemis = 475 nm [24].
Elworthy et al. [25] reported the use of o-phthalaldehyde (Fig. 8, 21)
as a derivatisation agent for TXA determination in plasma. In this case,
after deproteinization of the sample spiked with IS, the supernatant is
injected into the HPLC and the derivatisation occurs online by addition
of the o-phthalaldehyde to the column eluent. The derivatives formed
are detected using 410 nm and 450 nm as excitation and emission
wavelengths, respectively. o-Phthalaldehyde (OPA) is one of the most
sensitive fluorogenic compounds available for reaction with primary
amines and the derivatives formed are somewhat unstable whichFig. 9. Chemical structures of derivatising agents applied in UV–Visible detection of TXA,
including of 2-hydroxy-1-naphthaldehyde (24), ofloxacin acyl chloride (25), ninhydrin
(26) and phenyl isothiocyanate (27).
severely limits the use of this reagent [51]. Nevertheless, this gradual
deterioration in buffer solution was circumvented by addition of
EDTA. OPA was also used to tag TXA, in this case off-line, for TXA con-
centration monitoring during cardiopulmonary bypass [28].
Huertas-Pérez et al. [29] described a LC-FL for the quantification of
TXA in platelet-poor plasma using naphthalene-2,3-dicarboxaldehyde
(NDA, Fig. 8, 22) and cyanide as derivatising reagents. NDA is widely
used as a derivatising reagent for the determination of amino com-
pounds and has significantly improved stability, when compared to
the corresponding OPA, while retaining the high fluorescence quantum
efficiencies [52]. Quantification of the NDA-labelled TXA is carried out
after LC at λexc = 440 nm and λemis = 520 nm and is stable up to 24 h
after derivatisation.
Dansyl chloride (Fig. 8, 23) was another derivatising agent chosen
for fluorescence detection of TXA in human plasma following RP-HPLC
[26]. In this case, the reaction between the analyte and the derivatising
agent has the disadvantage of requiring high temperatures (100 °C for
30 min).
Methods for the determination of TXA using UV–Vis spectropho-
tometry for detection also required previous labelling of the analyte,
crucial to increase sensitivity for detection in biological fluids. In Fig. 9,
the chemical structures of 2-hydroxy-1-naphthaldehyde [31], ofloxacin
acyl chloride (OAC) [43], ninhydrin [42,44], and phenyl isothiocyanate
(PITC) [30,32], which are the most frequently applied chromophores
for tagging TXA, are presented.
The derivatisation of TXA in blood samples with 2-hydroxy-1-
naphthaldehyde (Fig. 9, 24) was achieved by adding the derivatising re-
agent in aqueous ethanol at neutral pH in a 1:1 ratio [31]. The imple-
mentation of this method is cumbersome as a large amount of blood
(5 mL) is required for derivatisation with adequate sensitivity.
Ofloxacin acyl chloride (OAC, Fig. 9, 25) was chosen by Lin et al. [43]
as derivatisation reagent for TXA detection in human plasma. The
resulting TXA derivative displays a tertiary amino function and there-
fore an additional ionizablemoiety is addedwhichmakes the derivative
suitable for separation by CE. OAC has, however, to be prepared through
a one-step reaction between the commercially available ofloxacin and
thionyl chloride, a very toxic and reactive reagent. Also, due to high re-
activity of the acyl halide obtained, the residue is only dissolved in ace-
tonitrile and used without any purification being assumed that the
residue is constituted by OAC.
Ninhydrin (Fig. 9, 26) is one of the most common compounds
employed to label α-aminoacids for detection by colorimetric assays.
TXA reacts with ninhydrin in the presence of phosphate buffer via oxi-
dative deamination followed by condensation to form a deep purple
compound which is then detected [53]. Ninhydrin reacts selectively
with free alpha-amino groups and does not react, for example, with ter-
tiary or aromatic amines. This derivatising agent was used by Okamoto
et al. [44] in rabbit plasma samples and Eriksson et al. [42] in human
urine and plasma samples.
Phenyl isothiocyanate (PITC, Fig. 9, 27) was first used by
Matsubayashi et al. [30] to introduce a chromophore in TXA occur-
ring in human serum to be analysed by HPLC-UV. The serum sample
was initially spiked with IS (Table 2) and after sample treatment, the
supernatant was treated with 10 mM borax solution (pH 9.2) and
PITC. After a laborious LLE procedure the final extract was resus-
pended in mobile phase to be injected into the chromatographic sys-
tem. This derivatisation agent was applied, almost 20 years later, by
Hadad et al. [32] to determine TXA concentration in human urine
samples and to investigate the pattern of urinary excretion of this
drug by a healthy male. In this case, phosphate buffer was added
first to the urine sample, followed by PITC in a methanol solution
(1% v/v). The reaction conditions used with PITC are slightly harsher
and the derivatisation time is longer (20–30 min at 40–60 °C) when
considering this type of samples and the conditions applied to other
derivatising reagents. A more modern approach was taken by Liao et
al. [45] using accelerated microwave assisted derivatisation anddispersive liquid-liquid microextraction (DLLME). Dansyl chloride
(Fig. 8, 23) was chosen to derivatise TXA present in human plasma,
among other matrices, followed by LC-UV. The time of derivatisation
reaction was reduced to 4 min (at 400 W).
Volatility of sample is a requirement for GC analysis. Derivatisation
must provide highly polar compounds sufficiently volatile so that
they can be eluted at reasonable temperatures avoiding thermal de-
composition or molecular re-arrangement. Also, in particular for
TXA, derivatisation can improve resolution and can reduce tailing
because this molecule contains quite polar functional groups
(\\COOH and\\NH2), which are known to contribute to these effects
through the formation of intermolecular hydrogen bonds.
Different derivatisation procedures have been applied for the detec-
tion of TXA in biological matrices by GC–MS. An early work of Miyazaki
et al. [33] on the determination of TXA in human serum considers a si-
multaneous amidation and esterification of the drug (Fig. 4) using
heptafluorobutyric anhydride as derivatising agent. The derivatisation
procedure is rather complex and time consuming and entails purifica-
tion by column chromatography over silica gel. Ethyl chloroformate
was also used as derivatising reagent for the determination of TXA by
a gas chromatographic procedure (Fig. 4, 5) [41]. In this case, after the
derivatisation procedure, a simple extraction with chloroform is re-
quired to collect the carbamate derivatives in the organic layer.
The insertion of an N-(2′-nitro-4′-trifluoromethylphenyl) moiety
into TXA (Fig. 4, 6) enhanced its detectability by electron capture [49].
This derivatisation process is rather long and several parameters should
be controlled, namely the competing hydrolyses of the derivatising re-
agent and the reaction rate that is dependent on the type and composi-
tion of solvent used, reagent concentration and pH [49].
3. Quantification of TXA
Concerning the practical application of the described quantification
techniques to clinical medicine, TXA concentration has beenmonitored
mainly in cardiopulmonary bypass surgery [28,36,37,40]. Pharmacoki-
netic studies have also been performed in patients undergoing ortho-
paedic surgery and after intravenous administration to normal
volunteers [39,42]. The bioavailability of TXA after administration of
an intramuscular dose was also studied in healthy male volunteers
[26]. The usual tranexamic acid plasma concentration observed for car-
diac surgery 1 h after discontinuation of TXA infusion, reported in the
literature,was 17.7 μgmL−1 [28]. Bojko et al. [40] reported that, patients
undergoing heart surgery with the use of CPB showed, after discontinu-
ation of TXA infusion, an average concentration of 72 μg mL−1.
Methods based on LC-MS/MS applied to the TXA quantification in bi-
ological fluids, particularly blood plasma, allowed detection limits rang-
ing from 0.01 to 0.5 μg mL−1 [34–40]. The lowest LOD and LOQ values
(0.01 and 0.02 μg mL−1) were attained for TXA extracted from a 200
μL of plasma sample [34]. The lower the LOQ value, more suitable is
the method developed for the measuring of TXA in plasma collected
to determine the clearance of the drug from the system after surgery
or even its concentration during the clinical procedure. TXA recovery
from plasma, determined for four levels of concentration, ranged from
99.07% to 102.09% while the IS recovery averaged 97.93%. This method,
developed by Chang et al. [34], showed linearity over a concentration
range of 0.02–10.00 μg mL−1 with the calibration curve being split in
two concentration ranges. The authors reported that matrix compo-
nents in plasma did not cause significant changes in the MS/MS re-
sponse of TXA with the percent of ion suppression being b2.09%
across QC sample levels. Also, studies on the inter-lot matrix variability,
using TXA at 1.5 μg mL−1, showed no significant variation in the peak
area ratio (RSD b 3.84%) [34].
The concomitant quantification of tranexamic acid with rocuronium
bromide in human plasma using a LC-MS/MS method provided higher
LOQ (0.1 μg mL−1) and LOD value (0.04 μg mL−1) values [38] despite
the larger sample volume (800 μL). Linearity was obtained over the
range 0.25–300 μg mL−1 and the extraction recovery values ranged be-
tween 1.1% and 1.4%. This recovery values are typical of a non-exhaus-
tive SPME pre-treatment of the sample.
There is only one report considering the quantification of TXA in
serum by application of a LC-MS/MS methodology. This method, de-
veloped by Delyle et al. [35], showed linearity over a concentration
range of 1.0–200.0 μg mL−1 which makes it suitable for quantifica-
tion of TXA in clinical studies. The LOD and LOQ values obtained
were of 0.05 and 1.0 μg mL−1, respectively. The mean overall recov-
ery of TXAwas 85.8% while the meanmatrix effect was 102.0% which
indicates the absence of any matrix effect in this method. The
amount of serum used in this method was small (100 μL) when
compared to other reported methods which makes it suitable when
considering paediatric patients. The method was applied to a phar-
macokinetic study which comprised two adult patients that were
subjected to cardiac surgery and two different dose regiments. For
the highest dose administered (total dose of 34 mg/kg), serum con-
centrations after baseline were between 142.6 and 198.5 μg mL−1,
while the lowest dose (total dose of 12 mg/kg) provided values be-
tween 19.0 and 53.6 μg mL−1 under similar conditions [35].
For LC-FL methods, higher LOD and LOQ were obtained. The limit of
detection and quantification reported by Huertas-Pérez et al. [29] was
0.08 and 0.2 μg mL−1. Linearity was observed for concentrations rang-
ing from 0.08 to 7.86 μg mL−1. Recovery assays performed in whole
blood samples revealed a constant negative bias, which was not ob-
served for plasma. Puigdellivol et al. [26] reported a LOD value 2.5
times higher for the same type of biological samples using a different
sample treatment procedure and another derivatising agent (Table 3).
For serum samples, the LOD obtained was of 4 μg mL−1 and linearity
was observed over a concentration range of 25 to 200 μg mL−1 [24].
The lowest limit of detection value obtained when using fluores-
cence detection was achieved for the determination of a prodrug of
TXA in dog's whole blood [27], which was ca. 0.001–0.003 μg mL−1
using a 500 μL sample volume. This valuewas dependent on the volume
of blood collected andhowmuchof the organic layer could be taken and
used for further re-extraction into the aqueous phase. This method
showed linearity over a concentration range of 0.01–0.1 μg mL−1.
The simultaneous determination of tranexamic acid and losartan po-
tassium concentration in human serum samples was performed after
protein precipitation and without any derivatisation step [46]. LOD
and LOQ of 0.012 and 0.040 μg mL−1 were attained, with good linearity
in the concentration range between 0.04 and 10 μg mL−1, showing re-
coveries higher than 97.8%.
In what concerns TXA determination in plasma samples using a LC-
UV system, the method developed by Liao et al. [45] showed a low LOD
at 0.02 μgmL−1. This samemethod applied to HaCaT cells led to a lower
LOD of 0.0002 μgmL−1. Themethod showed linearity over a concentra-
tion range of 0.8–78.6 μg mL−1.
A less studied biologicalmatrix, for the quantification of TXA, is urine
with only two reports found in the literature [32,42]. Hadad et al. [32]
reported a LOD and LOQ of 0.04 and 0.13 μg mL−1, respectively, using
LC-UV. For this matrix, mean recovery of TXA was 100.18%.
Serum samples containing TXA were also analysed by GC-EI leading
to LOD and LOQ of 0.2 and 0.6 μg mL−1, with linearity in the concentra-
tion range between 0.6 and 5.0 μg mL−1. The method showed recovery
of tranexamic acid added to deproteinized serum of 99.6% [41].4. Conclusions
Although TXA has been in use for several years in clinical practice,
there is a large variation inwhat is the recommended dose and standard
protocols for the determination of plasma concentration of this drug
during clinical procedures. Therefore, for the study of TXA pharmacoki-
netics in humans, a simple, fast, cheap and validated method for deter-
mination in biological fluids, such as plasma, is still required.This review has outlined conventional and more up-to-date separa-
tion and detection techniques used for the quantification of tranexamic
acid in biological fluids.While it has been shown herein thatmany stud-
ies have traditionally used spectrophotometric detection methods
coupled to liquid chromatography, current research is tuning to liquid
chromatography couple to tandem mass spectrometry. LC-MS/MS has
been, over recent years, the technique of choice since it allows increased
sensitivity and the ability to measure, in complex matrices such as plas-
ma or serum, down to the ng mL−1 range. However, application of this
technique still requires attention to ion suppression/enhancement,
studies on the efficiency of analyte ionization, and the need for a suit-
able internal standard.
There is also an increased need for method development in what
concerns application of describedmethods to a large number of sam-
ples. This necessarily relates to automated sample preparation that
would allow shorter analysis time. Therefore, automated sample
preparation with direct sample injection into the LC system could
be an important step forward in TXA sample pre-treatment. This
will improve, not only the analytical throughput, but also reduce sig-
nificantly the need for manipulation of biological materials leading
to the improved safety of laboratory personnel involved in clinical
practice routines.Acknowledgments
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